UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 16, 2018

 

 

 

AVADEL PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

 

 

 

Ireland

  001-37977

98-1341933

(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

Block 10-1
Blanchardstown Corporate Park, Ballycoolin

Dublin 15, Ireland

 

Not Applicable

(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +353 1 485 1200

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 1.01Entry into a Material Definitive Agreement.

 

On February 16, 2018, Avadel Pharmaceuticals plc (the “Company”), together with its subsidiaries Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., FSC Therapeutics LLC (“FSC Therapeutics”), and Avadel US Holdings, Inc. (“Holdings”), as the “Sellers,” completed the previously announced disposition of four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™, together with certain associated business assets – to Cerecor, Inc. (“Cerecor”), pursuant to the terms of an asset purchase agreement between the Sellers and the Buyer dated as of February 12, 2018 (the “Purchase Agreement”). Certain additional details of the Purchase Agreement and the transactions contemplated thereby (collectively, the “Transaction”) were set forth in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on February 12, 2018.

 

In connection with the closing of the Transaction, the Company or one of its subsidiaries entered into a License and Development Agreement, a Deerfield Guaranty and an Armistice Guaranty, each as hereinafter defined.

 

License and Development Agreement

 

In connection with the closing under the Purchase Agreement, on February 16, 2018 Flamel Ireland Limited, an Irish limited company operating under the trade name of Avadel Ireland (“Avadel Ireland”) and a wholly-owned subsidiary of the Company, and Cerecor entered into a license and development agreement (the “License and Development Agreement”), effective as of February 16, 2018, pursuant to which, among other things:

 

·Avadel Ireland will provide Cerecor with four product formulations utilizing Avadel Ireland’s LiquiTime™ technology, and will complete pilot bioequivalence studies for such product formulations within 18 months;

 

·Cerecor will reimburse Avadel Ireland for development costs of the four LiquiTime™ products in excess of $1 million in the aggregate;

 

·Upon transfer of the four product formulations, Cerecor will assume all remaining development costs and responsibilities for the product development, clinical studies, NDA applications and associated filing fees; and

 

·Upon regulatory approval and commercial launch of any LiquiTime™ products, Cerecor will pay Avadel Ireland quarterly royalties based on a percentage of net sales of any such products in the mid-single digits.

 

The foregoing summary of the License and Development Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the License and Development Agreement. The Company intends to submit a FOIA Confidential Treatment Request with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 for certain portions of the License and Development Agreement. The License and Development Agreement, in redacted form subject to such confidential treatment request, will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

2

 

 

Deerfield Guarantee

 

In connection with the closing under the Purchase Agreement, on February 16, 2018, the Company and Holdings provided their guarantee (the “Deerfield Guarantee”) in favor of Deerfield CSF, LLC, Peter Steelman and James Flynn (“Deerfield”). Under the Deerfield Guarantee, the Company and Holdings guaranteed to Deerfield the payment by Cerecor of the obligations of the Company and certain of its subsidiaries (the “Assumed Obligations”) under the Membership Interest Purchase Agreement between the Company and Deerfield dated February 5, 2016. The Assumed Obligations include (i) a quarterly payment of $262,500 beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of $2,625,000; (ii) a payment in January 2021 of $15,262,500; and (iii) a quarterly royalty payment of 15% on net sales of the FSC products through February 6, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately $10,300,000. In addition, under the Deerfield Guarantee, the Company and Holdings guaranteed that Deerfield would receive certain minimum annual FSC Product Royalties through February 6, 2026 (the “Minimum Royalties”).

 

The foregoing summary of the Deerfield Guarantee does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the Deerfield Guarantee, which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

Armistice Guarantee

 

In connection with the closing under the Purchase Agreement, on February 16, 2018, Armistice Capital Master Fund, Ltd. (“Armistice”), the majority shareholder of Cerecor, guaranteed to Holdings the payment by Cerecor of the Assumed Obligations, including the Minimum Royalties.

 

The foregoing summary of the Armistice Guarantee does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the Armistice Guarantee, which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

 

Item 2.01Completion of Acquisition or Disposition of Assets.

 

See Item 1.01 above, which is incorporated by reference herein.

 

3

 

 

Item 9.01Financial Statements and Exhibits.

 

(b)Pro Forma Financial Information

 

Attached as Exhibit 99.1 hereto are the following:

 

·Explanatory Note and Basis of Presentation with respect to Unaudited Pro Forma Condensed Combined Financial Statements.

 

·Unaudited pro forma condensed combined balance sheet of the Company as of September 30, 2017 (and notes thereto).

 

·Unaudited pro forma condensed combined balance sheet of the Company as of December 31, 2016 (and notes thereto).

 

·Unaudited pro forma condensed combined statement of income (loss) of the Company for the nine months ended September 30, 2017 (and notes thereto).

 

·Unaudited pro forma condensed combined statement of income (loss) of the Company for the twelve months ended December 31, 2016 (and notes thereto).

 

(d)Exhibits

 

99.1   Unaudited pro forma financial information, consisting of:
     
    · Explanatory Note and Basis of Presentation with respect to Unaudited Pro Forma Condensed Combined Financial Statements.
       
    · Unaudited pro forma condensed combined balance sheet of the Company as of September 30, 2017 (and notes thereto).
       
    · Unaudited pro forma condensed combined balance sheet of the Company as of December 31, 2016 (and notes thereto).
       
    · Unaudited pro forma condensed combined statement of income (loss) of the Company for the nine months ended September 30, 2017 (and notes thereto).
       
    · Unaudited pro forma condensed combined statement of income (loss) of the Company for the twelve months ended December 31, 2016 (and notes thereto).
       

 

4

 

 

Cautionary Note Regarding Forward-Looking Statements

 

This report contains forward-looking statements, including, but not limited to, statements related to the Company’s sale of its pediatric assets to Cerecor, the Company’s ability to develop four new pediatric products under its license and development agreement with Cerecor, the Company’s business strategy and development plans, expected financial performance in future periods, expected timing of clinical, regulatory and commercial events, and other statements that are not historical facts. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although we believe that the forward-looking statements contained in this report are based on reasonable assumptions within the bounds of our knowledge of our business and operations, our business is subject to significant risks and there can be no assurance that actual results will not differ materially from the expectations expressed in the forward-looking statements contained in this report. We undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise. You should not place undue reliance on these forward-looking statements. Except as required by law, we specifically disclaim any obligation to update such forward-looking statements.

 

5

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AVADEL PHARMACEUTICALS PLC  
       
  By: /s/ Michael F. Kanan  
    Michael F. Kanan  
    Senior Vice President and  
    Chief Financial Officer  

 

Date: February 23, 2018

  

 

 

 

Exhibit Index

 

99.1   Unaudited pro forma financial information, consisting of:
     
    · Explanatory Note and Basis of Presentation with respect to Unaudited Pro Forma Condensed Combined Financial Statements.
       
    · Unaudited pro forma condensed combined balance sheet of the Company as of September 30, 2017 (and notes thereto).
       
    · Unaudited pro forma condensed combined balance sheet of the Company as of December 31, 2016 (and notes thereto).
       
    · Unaudited pro forma condensed combined statement of income (loss) of the Company for the nine months ended September 30, 2017 (and notes thereto).
       
    · Unaudited pro forma condensed combined statement of income (loss) of the Company for the twelve months ended December 31, 2016 (and notes thereto).
       

  

2

 

Exhibit 99.1

 

Avadel Pharmaceuticals plc

Unaudited Pro Forma Condensed Combined Financial Information

 

Overview

 

On February 16, 2018, Avadel Pharmaceuticals plc (the “Company”), together with its subsidiaries Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., FSC Therapeutics LLC (“FSC Therapeutics”), and Avadel US Holdings, Inc. (“Holdings”), as the “Sellers,” completed the previously announced disposition of four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™, together with certain associated business assets (the “Pediatrics Business”) – to Cerecor, Inc. (“Cerecor”), pursuant to the terms of an asset purchase agreement between the Sellers and the Buyer dated as of February 12, 2018 (the “Purchase Agreement”). Certain additional details of the Purchase Agreement and the transactions contemplated thereby (collectively, the “Transaction”) were set forth in a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on February 12, 2018.

 

Pro forma Financial Information

 

Set forth below are the following:

     
  · Unaudited pro forma condensed combined balance sheet of the Company as of September 30, 2017 (and notes thereto).
     
  · Unaudited pro forma condensed combined balance sheet of the Company as of December 31, 2016 (and notes thereto).
     
  · Unaudited pro forma condensed combined statement of income (loss) of the Company for the nine months ended September 30, 2017 (and notes thereto).
     
  · Unaudited pro forma condensed combined statement of income (loss) of the Company for the twelve months ended December 31, 2016 (and notes thereto).

 

Basis of Presentation

 

The unaudited pro forma condensed combined financial statements reflect adjustments to the Company’s historical financial results as reported under the U.S. Generally Accepted Accounting Principles ("GAAP") in connection with the Transaction. The unaudited pro forma condensed combined balance sheet as of December 31, 2016 and the unaudited pro forma condensed combined statement of income (loss) for the twelve months then ended give effect to the sale of the Pediatrics Business as if the Transaction occurred on February 5, 2016 (the date the Pediatrics Business was acquired). The unaudited pro forma condensed combined balance sheet as of September 30, 2017 and the unaudited pro forma condensed combined statement of income (loss) for the nine months then ended give effect to the sale of the Pediatrics Business as if the Transaction occurred on January 1, 2017.

The unaudited pro forma condensed combined financial statements included below are being provided for information purposes only and are not necessarily indicative of the results of operations or financial position that would have resulted if the Transaction had actually occurred on the date indicated and are not intended to project the Company’s results of operations or financial position for any future period. The pro forma adjustments are based on available information and assumptions that the Company believes are attributable to the sale of the Pediatrics Business, are factually supportable, and with respect to the statement of income (loss), have continuing impact on the consolidated results.

 

The unaudited pro forma condensed combined financial statements and the accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017.

 

 

 

 

Avadel Pharmaceuticals plc

Unaudited Pro Forma Condensed Combined Balance Sheet

 

  

As of September 30, 2017

 
(in thousands)  As Reported   (1)
Adjustments
   Pro Forma 
ASSETS        
Current assets:               
Cash and cash equivalents  $37,449   $-   $37,449 
Marketable securities   78,161    -    78,161 
Accounts receivable   24,080    -    24,080 
Other current assets   9,243    445    8,798 
Total current assets   148,933    445    148,488 
Goodwill   18,491    -    18,491 
Intangible assets, net   94,256    18,495    75,761 
Other long-term assets   15,747    190    15,557 
Total assets  $277,427   $19,130   $258,297 
                
LIABILITIES AND SHAREHOLDERS' EQUITY               
Current liabilities:               
Current portion of long-term related party payable  $30,986   $1,902   $29,084 
Accounts payable and accrued expenses   56,561    -    56,561 
Other current liabilities   9,761    -    9,761 
Total current liabilities   97,308    1,902    95,406 
Long-term related party payable, less current portion   76,131    20,793    55,338 
Other long-term liabilities   7,525    -    7,525 
Total liabilities   180,964    22,695    158,269 
                
Total shareholders' equity   96,463    (3,565)   100,028 
Total liabilities and shareholders' equity  $277,427   $19,130   $258,297 

 

Notes to Unaudited Pro Forma Condensed Combined Balance Sheet

 

(1)The divestiture adjustments include the reversal of certain assets and liabilities related to the disposition of four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™. No adjustments have been made to give effect to the Deerfield and Armistice Guarantees and the impact of Avadel’s retained obligation related to a certain supply contract.

 

 

 

Avadel Pharmaceuticals plc

Unaudited Pro Forma Condensed Combined Balance Sheet

 

   As of December 31, 2016 
(in thousands)  As Reported   (1)
Adjustments
   Pro Forma 
ASSETS               
Current assets:               
Cash and cash equivalents  $39,215   $-   $39,215 
Marketable securities   114,980    -    114,980 
Accounts receivable   17,839    -    17,839 
Other current assets   9,152    1,623    7,529 
Total current assets   181,186    1,623    179,563 
Goodwill   18,491    -    18,491 
Intangible assets, net   22,837    19,577    3,260 
Other long-term assets   22,968    230    22,738 
Total assets  $245,482   $21,430   $224,052 
                
LIABILITIES AND SHAREHOLDERS' EQUITY               
Current liabilities:               
Current portion of long-term related party payable  $34,177   $1,233   $32,944 
Accounts payable and accrued expenses   24,327    -    24,327 
Other current liabilities   3,917    -    3,917 
Total current liabilities   62,421    1,233    61,188 
Long-term related party payable, less current portion   135,170    21,057    114,113 
Other long-term liabilities   5,822    -    5,822 
Total liabilities   203,413    22,290    181,123 
                
Total shareholders' equity   42,069    (860)   42,929 
Total liabilities and shareholders' equity  $245,482   $21,430   $224,052 

  

Notes to Unaudited Pro Forma Condensed Combined Balance Sheet

 

(1)The divestiture adjustments include the reversal of certain assets and liabilities related to the disposition of four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™. No adjustments have been made to give effect to the Deerfield and Armistice Guarantees and the impact of Avadel’s retained obligation related to a certain supply contract.

 

 

 

Avadel Pharmaceuticals plc

Unaudited Pro Forma Condensed Combined Statement of Income (Loss)

 

  

Nine months ended September 30, 2017

 
(in thousands)  As Reported   (1)
Adjustments
   Pro Forma 
Total revenue  $138,493   $5,341   $133,152 
                
Operating expenses:               
Cost of products and services sold   12,253    2,194    10,059 
Research and development expenses   22,093    20    22,073 
Selling, general and administrative expenses   35,804    9,300    26,504 
Changes in fair value of related party contingent consideration   (30,107)   1,336    (31,443)
Other costs   4,865    1,080    3,785 
Total operating expenses   44,908    13,930    30,978 
Operating income (loss)   93,585    (8,589)   102,174 
Other nonoperating income (expense)   4,761    (766)   5,527 
Income (loss) before income taxes   98,346    (9,355)   107,701 
Income tax provision (benefit)   21,830    (2,806)   24,636 
Net income (loss)  $76,516   $(6,549)  $83,065 
                
Net income per share - basic  $1.87        $2.03 
Net income per share - diluted   1.81         1.97 
                
Weighted average number of shares outstanding - basic   40,839         40,839 
Weighted average number of shares outstanding - diluted   42,194         42,194 

 

Notes to Unaudited Pro Forma Condensed Combined Statement of Income (Loss)

 

(1)The divestiture adjustments include the reversal of certain results of operations related to the disposition of four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™. No adjustments have been made to give effect to the Deerfield and Armistice Guarantees and the impact of Avadel’s retained obligation related to a certain supply contract.

 

 

 

Avadel Pharmaceuticals plc
Unaudited Pro Forma Condensed Combined Statement of Income (Loss)

 

   Twelve months ended December 31, 2016 
(in thousands)  As Reported   (1)(2)
Adjustments
   Pro Forma 
Total revenue  $150,246   $5,985   $144,261 
              - 
Operating expenses:               
Cost of products and services sold   13,248    2,929    10,319 
Research and development expenses   34,611    22    34,589 
Selling, general and administrative expenses   44,179    9,710    34,469 
Changes in fair value of related party contingent consideration   49,285    1,076    48,209 
Other costs   13,888    1,324    12,564 
Total operating expenses   155,211    15,061    140,150 
Operating income (loss)   (4,965)   (9,076)   4,111 
Other nonoperating expenses   (4,753)   (1,099)   (3,654)
Income (loss) before income taxes   (9,718)   (10,175)   457 
Income tax provision (benefit)   31,558    (3,184)   34,742 
Net loss  $(41,276)  $(6,991)  $(34,285)
                
Net loss per share - basic  $(1.00)       $(0.83)
Net loss per share - diluted   (1.00)        (0.83)
                
Weighted average number of shares outstanding - basic   41,248         41,248 
Weighted average number of shares outstanding - diluted   41,248         41,248 

  

Notes to Unaudited Pro Forma Condensed Combined Statement of Income (Loss)

 

(1)The divestiture adjustments include the reversal of certain results of operations related to the disposition of four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™. No adjustments have been made to give effect to the Deerfield and Armistice Guarantees and the impact of Avadel’s retained obligation related to a certain supply contract.

 

(2)The Adjustments column includes results of the Pediatric Business from February 5, 2016 (date of acquisition) through December 31, 2016.